CTOs on the Move

Prescos

www.prescos.com

 
Prescos is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.prescos.com
  • 3550 General Atomics Ct
    San Diego, CA USA 92121
  • Phone: 858.452.2001

Executives

Name Title Contact Details

Similar Companies

G-Biosciences/ Genotech

G-Biosciences/ Genotech is a Maryland Heights, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beeken Biomedical

We are focused on the development, licensing and commercialization of wound care products. Its innovative Hemafiber Technology™ enables first responders and hospital patient care providers to rapidly control bleeding by using the NuStat products to es...

Meissa Vaccines

Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens.

Miragen Therapeutics

miRagen Therapeutics, Inc., is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. From its founding, miRagen has developed ongoing, collaborative relationships with academic institutions that give the company unique access to the most promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of miRNA-targeting therapeutics.

Ribon Therapeutics

Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.